AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Universe Pharmaceuticals Inc. Class A Ordinary Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00WRF66B4
4.34▼ 0.04 (-0.91%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
4.38
Day's Range
4.11 – 4.53
52-Week Range
2.00 – 17.96
Volume
155.3K
Avg Volume
59.5K
Share Statistics
Shares Outstanding
Employees
216
Exchange
XNAS
Listed
2021-03-23
Share count as of September 30, 2025

Universe Pharmaceuticals Inc. Class A Ordinary Shares (UPC) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Universe Pharmaceuticals Inc. Class A Ordinary Shares (UPC)
What is Universe Pharmaceuticals Inc. Class A Ordinary Shares's Market Cap?
Universe Pharmaceuticals Inc. Class A Ordinary Shares's Market Cap is $2.4M, based on as-reported figures from SEC (XBRL) filings.
What is Universe Pharmaceuticals Inc. Class A Ordinary Shares's Enterprise Value?
Universe Pharmaceuticals Inc. Class A Ordinary Shares's Enterprise Value is -$24.3B, based on as-reported figures from SEC (XBRL) filings.
What is Universe Pharmaceuticals Inc. Class A Ordinary Shares's Price / Sales?
Universe Pharmaceuticals Inc. Class A Ordinary Shares's Price / Sales is 0.0×, based on as-reported figures from SEC (XBRL) filings.
What is Universe Pharmaceuticals Inc. Class A Ordinary Shares's EV / Revenue?
Universe Pharmaceuticals Inc. Class A Ordinary Shares's EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Universe Pharmaceuticals Inc. Class A Ordinary Shares's EV / EBITDA?
Universe Pharmaceuticals Inc. Class A Ordinary Shares's EV / EBITDA is 10.1×, based on as-reported figures from SEC (XBRL) filings.
What is Universe Pharmaceuticals Inc. Class A Ordinary Shares's Revenue (TTM)?
Universe Pharmaceuticals Inc. Class A Ordinary Shares's Revenue (TTM) is $17.9B, based on as-reported figures from SEC (XBRL) filings.
What is Universe Pharmaceuticals Inc. Class A Ordinary Shares's Net Income (TTM)?
Universe Pharmaceuticals Inc. Class A Ordinary Shares's Net Income (TTM) is -$3.7B, based on as-reported figures from SEC (XBRL) filings.
What is Universe Pharmaceuticals Inc. Class A Ordinary Shares's EBITDA?
Universe Pharmaceuticals Inc. Class A Ordinary Shares's EBITDA is -$2.4B, based on as-reported figures from SEC (XBRL) filings.
What is Universe Pharmaceuticals Inc. Class A Ordinary Shares's Diluted EPS (TTM)?
Universe Pharmaceuticals Inc. Class A Ordinary Shares's Diluted EPS (TTM) is -6,518.39, based on as-reported figures from SEC (XBRL) filings.
What is Universe Pharmaceuticals Inc. Class A Ordinary Shares's EBITDA Margin?
Universe Pharmaceuticals Inc. Class A Ordinary Shares's EBITDA Margin is -13.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · UPCAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemSep 30, 2025Sep 30, 2024Sep 30, 2023Sep 30, 2022Sep 30, 2021Sep 30, 2020Sep 30, 2019
Revenue
YoY growth-22.4%
Cost of revenue
Gross profit
% of revenue35.3%
Operating expenses
Selling expenses
General and administrative expenses
Research and development expenses
Total operating expenses
% of revenue-51.6%
Loss from operations
% of revenue-16.3%
Other income (expenses)
Interest expense, net
Other (expense) income, net
Impairment of prepayments for construction in progress
Equity investment income
Total other expense, net
Loss before income tax expense
Income tax expense—
Net loss
% of revenue-20.6%
Net loss per share - Basic (in Dollars per share)
Net loss per share - Diluted (in Dollars per share)